ClinicalTrials.gg
RecruitingNCT05554835GENOMITUpdated Aug 7, 2026

Global Registry and Natural History Study for Mitochondrial Disorders

An observational study in Mitochondrial Diseases, Kearns-Sayre Syndrome and MIDD, sponsored by LMU Klinikum. Recruiting at 34 sites in 3 countries. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by LMU Klinikum · Observational

How we know

From the registry’s dates

  • Started Feb 2009; still recruiting 17 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Mitochondrial Diseases with a site in Germany — 5 open to participants now, 5 under way, 1 of them phase 3. Mitochondrial Diseases · Germany.

Started
2009
the only one that year
Observational
6 of 15
3 open now
Registered
9th of 15
by date
Lead sponsor
1 of 15
LMU Klinikum

Among the 15 studies in Mitochondrial Diseases with a site in Germany, this one is the only one that started in 2009, is one of 6 observational ones, and was the 9th registered.

Mitochondrial Diseases

189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.

Browse Mitochondrial Diseases studies →

Open to participants now

5 of the 15 studies in Mitochondrial Diseases with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Mitochondrial Diseases with a site in Germany, or all of them as a file.
02

Study summary

The main goal of the project is provision of a global registry for mitochondrial disorders to harmonize previous national registries, enable world-wide participation and facilitate natural history studies, definition of outcome measures and conduction of clinical trials.

Read the detailed description

The global mitochondrial registry and natural history study is part of the EU-financed GENOMIT project, co-ordinated by Dr. Holger Prokisch, Technische Universität München (TUM).It aims at advancing the understanding of the natural history of mitochondrial disease to inform the design and facilitate the conduction of clinical trials. It also serves as a catalyst for translating basic research results into clinical practice.

The global mitochondrial registry and natural history study provides for all contingencies of national ethics and data protection rules including data access management.

Currently participating networks are:

  • German network for mitochondrial diseases - mitoNET, Germany/Austria
  • Italian Registry of Mitochondrial Patients - Mitocon, Italy

The inclusion of other networks and countries is possible and explicitly welcome. A major advantage of the global registry is that countries can join in, saving a lot of time, effort and funding.

03

Conditions studied

  • Mitochondrial Diseases
  • Kearns-Sayre Syndrome
  • MIDD
  • SANDO
  • SCAE
  • NARP Syndrome
  • MELAS Syndrome
  • MERRF Syndrome
  • Coenzyme Q10 Deficiency
  • LHON
  • MNGIE
  • MIRAS
  • Barth Syndrome
  • MDS
  • Mitochondrial Myopathies
  • Leigh Syndrome
  • Pearson Syndrome
  • CPEO

Keywords

  • Patient Registry
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • suspected or confirmed mitochondrial disease
  • willingness to participate

Exclusion criteria

Exclusion Criteria:

  • unwillingness to participate
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,000 participants (estimated)
Target follow-up
30 Years
Patient registry
Yes

Groups and cohorts

  • Mitochondrial patients

    Patients with a suspected or confirmed mitochondrial disease.

06

What researchers measure

Primary outcomes

  1. Newcastle Mitochondrial Disease Scale for Adults (NMDAS), Sections I-III

    Newcastle Mitochondrial Disease Scale for Adults (NMDAS) is a clinical rating scale designed for mitochondrial disease. The rating scale explores several domains: current function, system specific involvement and current clinical assessment. The individual scores are summed to provide a total score that ranges from 0 to 145; higher scores indicate more severely affection.

    Time frame: The individual participants are followed with annual assessments over a long time period (up to 30 years) or until discontinuation or death.

  2. Newcastle Pediatric Mitochondrial Disease Scale for Children (NPMDS)

    NPMDS is a clinical rating scale designed for mitochondrial disease in children. There are three versions of the NPMDS, each for a specific age range (0-24 months, 2-11 years, and 12-18 years). The rating scale explores several domains: current function (Section I), system specific involvement (Section II), current clinical assessment (Section III) and quality of life (QoL) assessments (Section IV). The individual scores in Section I-III are summed to provide a total score that ranges from 0 to 70 (version 0-24month) and 0-82 (versions 2-18 years); higher scores indicate more severely affection. Section IV (QoL) is scored separately and provide a total score that ranges from 0 to 25 with higher scores indicating better quality of life.

    Time frame: The individual participants are followed with annual assessments until they reach the next age group version (up to 18 years) or until discontinuation or death.

  3. Scale for the assessment and rating of ataxia (SARA) in adults

    The Scale for the Assessment and Rating of Ataxia (SARA) is a clinical scale used to assess cerebellar ataxia in adults. The scale includes 8 items, related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test. The individual scores are summed to provide a total score that ranges from 0 to 40, higher scores indicate more severe ataxia.

    Time frame: The individual participants are followed with annual assessments over a long time period (up to 30 years) or until discontinuation or death.

  4. Disease progression

    Disease progression as assessed by clinical examination and captured as HPO (Human Phenotype Ontology) Terms at each visit.

    Time frame: The individual participants are followed with annual assessments over a long time period (up to 30 years) or until discontinuation or death.

07

Study locations

34 of 34 sites recruiting
  • Medical University Innsbruck, Department of Pediatrics
    Innsbruck, 6020, Austria
    Recruiting
  • Salzburger Landeskliniken, SALK, Paracelsus Medizinische Privatuniversität
    Salzburg, 5020, Austria
    Recruiting
    • Saskia Wortmann, Prof. Dr. med. · Contacts.wortmann@salk.at · +43 5 7255
    • Katja Steinbrücker, Dr. · Contact+43 5 7255
    • Johannes Mayr, Dr. · Sub investigator
    • Wolfgang Sperl, Univ.-Prof. Dr. · Sub investigator
  • Department of Neurology, Klinikum Rechts der Isar, Technical University Munich
    Munich, Bavaria 81675, Germany
    Recruiting
  • Charité Virchow Klinikum, Klinik für Pädiatrie m. S. Neurologie
    Berlin, 13353, Germany
    Recruiting
  • Universität Bonn, Klinik und Poliklinik für Neurologie
    Bonn, Germany
    Recruiting
  • Universitätsklinikum Köln, Klinik und Poliklinik für Kinder- und Jugendmedizin
    Cologne, 50931, Germany
    Recruiting
  • Universitätsklinikum Düsseldorf, Klinik für allgemeine Pädiatrie, Neonatologie und Kinderkardiologie
    Düsseldorf, 40225, Germany
    Recruiting
  • Universitätsklinikum Frankfurt, Klinik für Kinder- und Jugendmedizin, Schwerpunkt Neurologie, Neurometabolik und Prävention
    Frankfurt am Main, 60590, Germany
    Recruiting
  • University Medical Center Freiburg, Center for children and youth medicine
    Freiburg im Breisgau, 79106, Germany
    Recruiting
  • Universitätsklinik und Poliklinik für Neurologie Universitätsmedizin Halle
    Halle, 06097, Germany
    Recruiting
  • Universitätsklinikum Hamburg Eppendorf Institut für Humangenetik
    Hamburg, 20246, Germany
    Recruiting
  • Universitätsklinikum Hamburg Eppendorf, Klinik für Kinder-und Jugendmedizin
    Hamburg, 20246, Germany
    Recruiting
    • Konstantinos Tsiakas, Dr.med. · Contacttsiakas@uke.de · +49 40 7410
    • Mathias Woidy, Dr. med. · Contactm.woidy@uke.de · +49 40 7410
  • Universitätsklinikum Hamburg Eppendorf, Klinik für Neurologie
    Hamburg, 20246, Germany
    Recruiting
  • Universitätsklinikum Heidelberg, Zentrum für Kinder- und Jugendmedizin, Sektion für Neuropädiatrie und Stoffwechselmedizin
    Heidelberg, 69120, Germany
    Recruiting
  • LMU Klinikum, Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik
    München, 80336, Germany
    Recruiting
  • LMU Klinikum
    München, 80337, Germany
    Recruiting
  • Klinikum am Steinenberg, Kreiskliniken Reutlingen, Klinik für Kinder-und Jugendmedizin, Perinatal- u. Stoffwechselzentrum
    Reutlingen, 72764, Germany
    Recruiting
    • Peter Freisinger, Prof. Dr. · Contactfreisinger_p@klin-rt.de · +49 7121 200 4051
    • Vanessa Kock, Dr. med. · Contact+49 7121 200 4060
  • Universitätsklinikum Tübingen, Neurologische Klinik und Hertie Institut für Klinische Hirnforschung
    Tübingen, 72076, Germany
    Recruiting
  • Sant'Orsola-Malpighi University Hospital
    Bologna, Italy
    Recruiting
  • University of Bologna
    Bologna, Italy
    Recruiting
    • Valerio Carelli, Prof. dr. · Contact
    • Valerio Carelli, Prof. dr. · Principal investigator
    • Chiara La Morgia · Sub investigator
  • University of Bologna
    Bologna, Italy
    Recruiting
  • Nemo Clinical Center
    Brescia, Italy
    Recruiting
  • University of Cagliari
    Cagliari, Italy
    Recruiting
    • Maria Antonietta Maioli, dr. med · Contactma.maioli@tiscali.it
    • Maria Antonietta Maioli · Principal investigator
  • AOU Meyer IRCCS Children's Hospital
    Florence, Italy
    Recruiting
    • Elena Procopio, dr. med · Contacte.procopio@meyer.it
    • Elena Procopio · Principal investigator
  • Giannina Gaslini Children's Hospital
    Genova, Italy
    Recruiting
  • University Hospital G. Martino
    Messina, Italy
    Recruiting
    • Olimpia Musumeci, Prof. dr. · Contactomusumeci@unime.it
    • Olimpia Musumeci · Principal investigator
  • IRCCS Foundation Ca' Granda - Ospedale Maggiore
    Milan, Italy
    Recruiting
    • Giacomo Pietro Comi, Prof. dr. · Contactgiacomo.comi@unimi.it
    • Giacomo Pietro Comi · Principal investigator
  • IRCCS Foundation Carlo Besta Neurological Institute
    Milan, Italy
    Recruiting
  • Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa & AOUP
    Pisa, Italy
    Recruiting
  • IRCCS Foundation Stella Maris
    Pisa, Italy
    Recruiting
    • Filippo Santorelli, dr. med · Contactfilippo3364@gmail.com
    • Filippo Santorelli · Principal investigator
  • Bambino Gesù Children's Hospital
    Rome, Italy
    Recruiting
    • Enrico Silvio Bertini, Prof. dr. · Contactenricosilvio.bertini@opbg.net
    • Enrico Silvio Bertini · Principal investigator
    • Diego Martinelli · Sub investigator
    • Daria Diodato · Sub investigator
  • University of Rome
    Rome, Italy
    Recruiting
    • Serenella Servidei, Prof. dr. · Contact
    • Serenella Servidei, Prof. dr. · Principal investigator
    • Guido Primiano, Prof. dr. · Sub investigator
  • AOU City of Health and Science of Turin - Molinette Hospital
    Turin, Italy
    Recruiting
  • AOUI Verona
    Verona, Italy
    Recruiting
08

References and documents

Publications

  • Stenton SL, Sheremet NL, Catarino CB, Andreeva NA, Assouline Z, Barboni P, Barel O, Berutti R, Bychkov I, Caporali L, Capristo M, Carbonelli M, Cascavilla ML, Charbel Issa P, Freisinger P, Gerber S, Ghezzi D, Graf E, Heidler J, Hempel M, Heon E, Itkis YS, Javasky E, Kaplan J, Kopajtich R, Kornblum C, Kovacs-Nagy R, Krylova TD, Kunz WS, La Morgia C, Lamperti C, Ludwig C, Malacarne PF, Maresca A, Mayr JA, Meisterknecht J, Nevinitsyna TA, Palombo F, Pode-Shakked B, Shmelkova MS, Strom TM, Tagliavini F, Tzadok M, van der Ven AT, Vignal-Clermont C, Wagner M, Zakharova EY, Zhorzholadze NV, Rozet JM, Carelli V, Tsygankova PG, Klopstock T, Wittig I, Prokisch H. Impaired complex I repair causes recessive Leber's hereditary optic neuropathy. J Clin Invest. 2021 Mar 15;131(6):e138267. doi: 10.1172/JCI138267. PubMed 33465056 ↗
  • Stendel C, Neuhofer C, Floride E, Yuqing S, Ganetzky RD, Park J, Freisinger P, Kornblum C, Kleinle S, Schols L, Distelmaier F, Stettner GM, Buchner B, Falk MJ, Mayr JA, Synofzik M, Abicht A, Haack TB, Prokisch H, Wortmann SB, Murayama K, Fang F, Klopstock T; ATP6 Study Group. Delineating MT-ATP6-associated disease: From isolated neuropathy to early onset neurodegeneration. Neurol Genet. 2020 Jan 13;6(1):e393. doi: 10.1212/NXG.0000000000000393. eCollection 2020 Feb. PubMed 32042921 ↗
  • Ng YS, Bindoff LA, Gorman GS, Klopstock T, Kornblum C, Mancuso M, McFarland R, Sue CM, Suomalainen A, Taylor RW, Thorburn DR, Turnbull DM. Mitochondrial disease in adults: recent advances and future promise. Lancet Neurol. 2021 Jul;20(7):573-584. doi: 10.1016/S1474-4422(21)00098-3. PubMed 34146515 ↗
  • Ng YS, Bindoff LA, Gorman GS, Horvath R, Klopstock T, Mancuso M, Martikainen MH, Mcfarland R, Nesbitt V, Pitceathly RDS, Schaefer AM, Turnbull DM. Consensus-based statements for the management of mitochondrial stroke-like episodes. Wellcome Open Res. 2019 Dec 13;4:201. doi: 10.12688/wellcomeopenres.15599.1. eCollection 2019. PubMed 32090171 ↗
  • Mancuso M, McFarland R, Klopstock T, Hirano M; consortium on Trial Readiness in Mitochondrial Myopathies. International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy. Neuromuscul Disord. 2017 Dec;27(12):1126-1137. doi: 10.1016/j.nmd.2017.08.006. Epub 2017 Sep 8. No abstract available. PubMed 29074296 ↗

Individual participant data

Plan to share: Yes — Any data or results from the project can be shared upon written request with researchers. Data sharing requires approval by the respective scientific committee and their institutional review board.

Supporting information: Informed consent form

Time frame: Time frame for data usage needs to be specified in the proposal for data sharing.

Access criteria: Approved written proposal including the description of the research plan and data usage purpose.

Data sharing details ↗ · www.mitonet.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2009 (actual). Primary completion is estimated for Dec 2040, 382 months after the start.

Of 33 observational studies under Mitochondrial Diseases, half reached primary completion within 169 months of starting (the median), counting those still running; a quarter within 26. This study's planned 382 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2022
First posted
Sep 26, 2022
StartActual
Feb 1, 2009
Primary completionEst.
Dec 2040
CompletionEst.
Dec 2040
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05554835
Lead sponsor
LMU Klinikum
Collaborators
European Commission, German Federal Ministry of Education and Research, University of Pisa
Responsible party
Prof. Thomas Klopstock (Prof. Dr. Thomas Klopstock, LMU Klinikum) — Principal investigator
First posted
Sep 26, 2022
Start date
Feb 1, 2009
Primary completion
Dec 2040 (estimated)
Completion
Dec 2040 (estimated)
Last update
Aug 7, 2026

Study contacts

Boriana Büchner, Dr.
Contact
boriana.buechner@med.uni-muenchen.de
+49 89 4400 ext. 57067
Thomas Klopstock, Prof. Dr.
principal investigator · LMU Klinikum, Munich
Michelangelo Mancuso, Prof. Dr.
principal investigator · Università di Pisa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion